Introduction {#s1}
============

Viruses encounter a remarkable array of intracellular antiviral defences that they must suppress or evade in order to replicate. The cyclophilin (Cyp) family of host proteins have emerged as key players at the virus-host interface. Cyclophilin A (CypA) is a cofactor for a variety of established and emerging viruses, including *Flaviviridae* such as hepatitis C virus (HCV) ([@bib73]) and dengue virus ([@bib54]), as well as *Coronaviridae* such as SARS coronavirus ([@bib52]). Like other Cyps, CypA has peptidyl prolyl isomerase activity, which is thought to induce conformational changes in bound target proteins ([@bib68]). Importantly, recruitment of CypA also affects protein complex formation ([@bib40]). The role of CypA as a viral cofactor is best understood for human immunodeficiency virus (HIV-1), where CypA binds to the viral capsid ([@bib43]; [@bib65]) to regulate interactions with downstream cofactors and protect the capsid and encapsidated viral genome from cellular innate immune sensors ([@bib55]; [@bib61]; [@bib34]). However, the mechanisms by which CypA contributes to other viral infections are less well understood.

Cyps have been implicated in the regulation of viral innate immune evasion ([@bib55]) and innate immune signalling ([@bib64]; [@bib42]; [@bib50]). In the case of HCV, clinical trials demonstrated that pharmacological inhibition of CypA suppressed HCV replication and led to elevated type one interferon (IFN) in patients ([@bib30]). Given the links between CypA and HCV innate immune evasion, we sought to understand the potential roles of CypA in viral innate immune evasion using HCV as a model. Both CypA binding and resistance to cyclophilin inhibitors (CypI) map to the HCV NS5A protein ([@bib27]; [@bib74]), which has essential roles in HCV replication and assembly ([@bib58]) and crucially also contributes to immune evasion by several key mechanisms. For example, NS5A is necessary for formation of the membranous replication organelle (RO) ([@bib56]) that cloaks viral RNA replication from cytosolic pattern recognition receptors ([@bib48]), preventing innate immune activation. Notably, CypA plays a role in the formation of the RO ([@bib45]; [@bib12]). NS5A also inhibits activation of the key antiviral effector protein kinase R (PKR) ([@bib22]) and subsequent PKR-dependent activation of interferon regulatory factor-1 (IRF1)-driven antiviral responses ([@bib53]).

Here we have used a panel of novel CypI alongside genetics approaches to discover that CypA regulates HCV evasion of PKR and IRF1 antiviral responses, and that diverse CypI overcome this evasion strategy leading to suppression of virus replication. Our findings advance understanding of CypA-HCV interactions and PKR mechanisms, and open perspectives for the development of novel CypA-targeted therapies that harness host intrinsic antiviral responses to combat infection.

Results {#s2}
=======

CypA is critical for HCV replication in Huh7 cells, but not in Huh7.5 cells {#s2-1}
---------------------------------------------------------------------------

To characterise the role of CypA in HCV innate immune evasion, we took advantage of the human hepatoma cell line Huh7 and its derivative Huh7.5. Huh7.5 cells were selected for enhanced ability to support HCV replication ([@bib6]) and spread ([@bib36]), and also have defective innate immunity ([@bib63]). We silenced CypA and CypB expression in Huh7 and Huh7.5 cells by stably expressing specific shRNAs ([Figure 1A--B](#fig1){ref-type="fig"}) and subsequently evaluated HCV replication using the subgenomic replicon (SGR) model. Silencing of CypB expression inhibited HCV replication by \~100 fold in both cell lines ([Figure 1C](#fig1){ref-type="fig"}), consistent with its previously described role in viral RNA replication ([@bib70]). Intriguingly, silencing of CypA abrogated HCV replication in Huh7 cells but had minimal effect in Huh7.5 cells ([Figure 1C](#fig1){ref-type="fig"}). We observed the same inhibition profile when the data were normalised to the input luciferase signal at 4 hr post-electroporation (hpe) ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}), confirming that this observation was not due to differences in electroporation efficiency between cell lines. The differential effect of CypA depletion was mirrored by treatment with the classical CypI cyclosporine A (CsA). CsA abrogated HCV replication in Huh7 cells, but only partially inhibited replication in Huh7.5 cells ([Figure 1D](#fig1){ref-type="fig"}). CsA also inhibited HCV replication in Huh7.5 cells silenced for CypA expression ([Figure 1E](#fig1){ref-type="fig"}), with similar antiviral potency regardless of CypA expression ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}). This suggests that the observed inhibition in Huh7.5 cells may result from inhibition of CypB, which is also a CsA target ([@bib15]). This observation explains the controversy of whether CypA or CypB are HCV cofactors, by demonstrating that both have roles, and suggests differential cofactor requirements between Huh7 and more permissive Huh7.5 cells.

![CypA is critical for HCV replication in Huh7 cells, but not in Huh7.5 cells.\
(**A**) Western blot detecting CypA (**A**) or CypB (**B**) expression in Huh7 and Huh7.5 cells transduced with Cyp specific shRNA-expressing lentiviruses as shown. Actin was detected as a loading control. (**C**) Evaluation of HCV replicon replication in CypA- and CypB-silenced cells. Luciferase reporter activity was measured at 4 and 48 hr post-electroporation (hpe) and is expressed as relative luciferase units (RLU) at 48 hpe. (**D-E**) Huh7 or Huh7.5 cells (silenced or not for CypA expression) were electroporated with replicon RNA and treated with 1 μM CsA at 4 hr post electroporation (hpe). Luciferase reporter activity was measured at 48 hr post-electroporation. (**F**) HCVcc infection in CypA-silenced Huh7 and Huh7.5 cells. Cells were infected with HCVcc (J6/JFH1-RLuc) and infection was assessed after 72 hr by measuring luciferase activity. (**G**) Huh7 or Huh7.5 cells were infected with HCVcc and treated with 1 μM CsA at 4 hr post-infection (hpi). After 72 hr, infection was measured by luciferase activity. (**H**) Replication of HCV NS5A wild-type (WT) and HCV CsA resistance mutant (NS5A D316E/Y317N; DEYN) in Huh7 and Huh7.5 cells. Cells were electroporated with in vitro transcribed replicon RNA as described above, and replication was assessed by luciferase activity at 48 hpe. (**I**) Huh7 or Huh7.5 cells were electroporated with HCV NS5A DEYN replicon RNA. After 4 hr, cells were treated with 1 μM CsA and replication was assessed by luciferase activity at 48 hpe. All graphs show relative luciferase units (RLU) expressed as means ± standard deviation from at least three independent experiments each performed in triplicate. Statistical significance was evaluated by t-test using GraphPad Prism (\*\*\*\* p-value\<0.0001; \*\* p-value\<0.01). Detection limits of the assays are shown by the dotted grey line.](elife-52237-fig1){#fig1}

We validated the differential cyclophilin dependence in Huh7 and Huh7.5 cells using the HCVcc (J6/JFH1-Rluc) infection model. Silencing of CypA expression, or addition of CsA, completely inhibited HCVcc infection in Huh7 cells, but only weakly inhibited infection in Huh7.5 cells ([Figure 1F--G](#fig1){ref-type="fig"}), which may reflect a role for CypA in HCV assembly ([@bib46]). To further probe this differential requirement for CypA, we evaluated replication of the CypA-independent NS5A D316E/Y317N (DEYN) mutant ([@bib74]), which was selected by CypI treatment in highly permissive HCV replicating cell lines. HCV DEYN replicated at wild type levels in Huh7.5 cells, but exhibited a 5-fold replication defect in innate immune competent Huh7 cells ([Figure 1H](#fig1){ref-type="fig"}). The replication defect in Huh7 cells was partially rescued by addition of CsA ([Figure 1I](#fig1){ref-type="fig"}). This observation mirrors similar observations for HIV-1 mutants selected to replicate in the presence of CsA in that they too become somewhat dependent on CsA for maximal replication ([@bib75]). Together, these results confirm that CypA is crucial for HCV replication in innate sensing competent Huh7 cells, but significantly less important for replication in more permissive Huh7.5 cells.

Structurally distinct CypI are more potent against HCV replication in Huh7 cells than in Huh7.5 cells {#s2-2}
-----------------------------------------------------------------------------------------------------

CsA binds to the cyclophilin active site and forms a ternary inhibitory complex with phosphatase calcineurin, which inhibits T cell proliferation leading to immunosuppression ([@bib40]). To confirm that the phenotype we observed with CsA treatment ([Figure 1](#fig1){ref-type="fig"}) was due to cyclophilin binding, and not off-target complex formation, and to generate chemical probes suitable for further mechanistic analyses, we synthesized a panel of novel CypI with distinct structures acting by distinct mechanisms. These included novel CsA analogues and synthetic small molecules based on sanglifehrin chemistry termed depsins ([Figure 2A](#fig2){ref-type="fig"}). The synthesis and favourable pharmacokinetic properties of depsin molecules were recently described ([@bib44]). Importantly, depsin molecules do not cause immunosuppression via the calcineurin pathway ([@bib76]). We also designed and synthesized a CsA-derived proteolysis targeting chimera (PROTAC; CsA-Prtc1) ([Figure 2A](#fig2){ref-type="fig"}), which is expected to recruit the von Hippel-Lindau E3 ubiquitin ligase to CsA targets, leading to their proteasomal degradation.

![Structures and properties of distinct novel CypI.\
(**A**) Structures of CypI used in this study; their effects on viral replication and cell viability are shown in Figure supplement 1. (**B**) CypI-CypA binding affinity measured by fluorescence polarisation using a fluorescein labelled CsA probe. (**C**) Western blot showing CsA-Prtc1-mediated degradation of CypA in Huh7 and Huh7.5 cells after 48 hr treatment with 1 μM CsA-Prtc1. (**D**) Analysis of CypA degradation at time points shown after 1 μM CsA-Prtc1 treatment in Huh7 cells detecting CypA expression by western blot. (**E**) Dose-response of CsA-Prtc1-mediated CypA degradation in Huh7 cells. Cells were treated with the indicated concentrations of CsA-Prtc1 for 48 hr, and CypA levels detected by western blot. (**F**) CsA-Prtc1-mediated degradation of CypA is proteasome-dependent. Cells were treated with CsA-Prtc1 (1 μM) with or without the proteasome inhibitor MG132 (10 μM) for 24 hr. CypA was detected by western blot. (**G**) CsA-Prtc1 specificity for CypA. Huh7 cells were treated with 1 μM CsA-Prtc1 for 24 hr and CypA, CypB or CypD detected by western blot. (**H**) Quantitation by densitometry of gel in (G) showing adjusted relative density normalised to the actin loading control. (**I**) CsA treatment rescues CypA from CsA-Prtc1-mediated degradation. Huh7 cells, treated for 24 hr with CsA-Prtc1 (100 nM), in the presence of increasing concentrations of CsA, were lysed and CypA expression detected by western blot. (**C-I**) One representative western blot is shown from at least two independent experiments; (**D-E**) quantitation by densitometry analysis (showing the combined data from the independent experiments) is shown in Figure supplement 2A-B.](elife-52237-fig2){#fig2}

In total, we evaluated \~80 novel CypI for their inhibitory effects on HCV replication in Huh7 cells. We selected the most potent antiviral, and least cytotoxic, molecule from each CypI type for further characterisation ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). Using a fluorescence polarisation assay, in which fluorescent CsA is competed from purified recombinant CypA with unlabelled CypI ([@bib69]), we first confirmed that the selected molecules bound to CypA with similar nanomolar affinities ([Figure 2B](#fig2){ref-type="fig"}). CsA-Prtc1 treatment led to degradation of CypA in Huh7 and Huh7.5 cells ([Figure 2C](#fig2){ref-type="fig"}) within a matter of hours ([Figure 2D](#fig2){ref-type="fig"}, [Figure 2---figure supplement 2A](#fig2s2){ref-type="fig"}) in a dose-dependent manner ([Figure 2E](#fig2){ref-type="fig"}, [Figure 2---figure supplement 2B](#fig2s2){ref-type="fig"}), with complete loss of detectable CypA protein expression occurring within 24 hr at concentrations as low as 100 nM. Degradation was proteasome-dependent ([Figure 2F](#fig2){ref-type="fig"}) with selectivity for CypA ([Figure 2G--H](#fig2){ref-type="fig"}), with minimal impact on CypB or CypD protein expression after 24 hr in Huh7 cells, although CypB degradation was observed after 48 hr incubation ([Figure 2---figure supplement 2C](#fig2s2){ref-type="fig"}). Moreover, CsA treatment protected CypA from CsA-Prtc1-mediated degradation ([Figure 2I](#fig2){ref-type="fig"}), illustrating CypA recruitment of CsA within cells.

We next compared the effect of our selected CypI on HCV replication and infection in Huh7 and Huh7.5 cells. Like CsA, our three novel and structurally distinct CypI abrogated HCV replication ([Figure 3A](#fig3){ref-type="fig"}) and HCVcc infection ([Figure 3B](#fig3){ref-type="fig"}) in Huh7 cells, but only partially inhibited replication and infection in Huh7.5 cells at the tested dose ([Figure 3A--B](#fig3){ref-type="fig"}). The CsA-Prtc1 was extremely potent and completely inhibited HCVcc infection in both cell lines at the single dose tested ([Figure 3B](#fig3){ref-type="fig"}). However, dose-response analyses showed that the CypI were similarly 5- to 10-fold more potent against HCV replication in Huh7 cells compared to Huh7.5 cells ([Figure 3C](#fig3){ref-type="fig"}), with low nanomolar IC~50~ in Huh7 cells ([Table 1](#table1){ref-type="table"}). The selected CypI were similarly more potent against HCVcc infection of Huh7 cells compared to Huh7.5 cells ([Figure 3D](#fig3){ref-type="fig"}, [Table 1](#table1){ref-type="table"}). Concordantly, while replication of the NS5A DEYN mutant was resistant to CypI treatment in Huh7.5 cells, CypI treatment dose-dependently enhanced DEYN replication in Huh7 cells ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}), again illustrating the differential requirements for CypA in the two cell lines during HCV replication.

![CypI are more potent against HCV replication and infection in Huh7 cells than in Huh7.5 cells.\
(**A**) CypI more potently inhibit HCV replication in Huh7 cells than in Huh7.5 cells. Huh7 or Huh7.5 cells electroporated with HCV replicon RNA were treated with 1 μM CypI at four hpe and replication was measured by luciferase activity after 48 hr. (**B**) CypI more potently inhibit HCVcc infection in Huh7 cells than in Huh7.5 cells. Cells infected with HCVcc were treated with 1 μM CypI at four hpi and replication was measured by luciferase activity after 72 hr. (**C-D**) Dose-response analyses comparing antiviral activity of CypI in Huh7 and Huh7.5 cells. Cells were electroporated with HCV replicon RNA (**C**) or infected with HCVcc (**D**) and treated with increasing concentrations of CypI four later. Replication or infection was measured by luciferase activity after 48 hr (**C**) or 72 hr (**D**), and is expressed as a percentage relative to the DMSO vehicle-treated control. All graphs show means ± standard deviation from at least three independent experiments each performed in triplicate. Detection limits of the assays are shown by the dotted grey line.](elife-52237-fig3){#fig3}

###### Comparison of CypI IC~50~ against HCV replication or infection in different cell lines.

  Replication (SGR)      IC~50~ (μM)                                     
  ---------------------- --------------- --------------- --------------- ---------------
  Cell line              CsA             CsA-like        Depsin          CsA-Prtc1
  Huh7                   0.188 ± 0.032   0.266 ± 0.037   0.043 ± 0.005   0.016 ± 0.002
  Huh7.5                 0.955 ± 0.123   1.374 ± 0.197   0.336 ± 0.053   0.055 ± 0.007
  Huh7.5-CTRL            0.373 ± 0.085   0.527 ± 0.154   0.206 ± 0.043   0.070 ± 0.013
  Huh7.5-RIG-I           0.560 ± 0.105   0.686 ± 0.181   0.243 ± 0.054   0.093 ± 0.019
  Huh7.5-Mda5            0.754 ± 0.160   0.950 ± 0.247   0.302 ± 0.060   0.100 ± 0.018
  Huh7.5-RIG-I/Mda5      0.820 ± 0.206   1.234 ± 0.298   0.351 ± 0.085   0.101 ± 0.021
  Huh7 NT c7             0.068 ± 0.008   0.184 ± 0.026   0.037 ± 0.004   0.009 ± 0.001
  Huh7 MAVS KO           0.112 ± 0.019   0.160 ± 0.023   0.056 ± 0.008   0.010 ± 0.001
  Huh7 MAVS KO + C508R   0.075 ± 0.014   0.141 ± 0.028   0.045 ± 0.006   0.008 ± 0.001
  Huh7 PKR KO c1         0.176 ± 0.034   0.971 ± 0.186   0.125 ± 0.021   0.021 ± 0.003
  Huh7 PKR KO c4         0.172 ± 0.040   1.249 ± 0.327   0.091 ± 0.015   0.028 ± 0.004
  Huh7 IRF1 KO c10       0.183 ± 0.042   1.219 ± 0.224   0.170 ± 0.039   0.027 ± 0.005
  Huh7 IRF1 KO c11       0.193 ± 0.047   1.593 ± 0.284   0.192 ± 0.045   0.040 ± 0.006
  Huh7 + DMSO            0.216 ± 0.050                                   
  Huh7 + C16             0.553 ± 0.098                                   
  Huh7.5 + DMSO          0.879 ± 0.131                                   
  Huh7.5 + C16           1.750 ± 0.495                                   
  HCVcc infection        IC~50~ (μM)                                     
  Cell line              CsA             CsA-like        Depsin          CsA-Prtc1
  Huh7                   0.043 ± 0.012   0.091 ± 0.020   0.096 ± 0.016   0.003 ± 0.001
  Huh7.5                 0.182 ± 0.037   0.316 ± 0.083   1.084 ± 0.373   0.014 ± 0.003
  Huh7 NT c7             0.033 ± 0.005   0.123 ± 0.023   0.018 ± 0.003   0.012 ± 0.002
  Huh7 PKR KO c4         0.095 ± 0.019   0.433 ± 0.101   0.051 ± 0.011   0.023 ± 0.005

Induction of cellular antiviral responses in Huh7 cells, but not in Huh7.5 cells, contributes to the antiviral potency of CypI against HCV {#s2-3}
------------------------------------------------------------------------------------------------------------------------------------------

Given that all of the CypI inhibited HCV more potently in innate immune competent Huh7 cells, we hypothesized that the increased potency might be due to induction of effective innate antiviral responses in parental Huh7 that were lacking in the more permissive Huh7.5 cells. To test this, we evaluated expression of IFN-β mRNA by qPCR after treating HCV-replicating or HCVcc-infected Huh7 or Huh7.5 cells with CsA. Consistent with our hypothesis, we observed induction of IFN-β expression in Huh7 cells but not in more permissive Huh7.5 cells ([Figure 4A--B](#fig4){ref-type="fig"}). Intriguingly, CsA-like molecules and structurally unrelated depsins, but not CsA-Prtc1 (which degrades CypA rather than simply binding CypA and affecting complex formation), were capable of inducing IFN-β expression in HCV-replicating Huh7 cells ([Figure 4C](#fig4){ref-type="fig"}). One possibility is that activation of IFN-β expression requires the presence of CypA, which is consistent with previous studies suggesting CypA is a necessary co-factor for innate immune sensors, including RIG-I ([@bib42]) and PKR ([@bib14]).

![CypI induce expression of IFN-β and antiviral genes in Huh7, but not Huh7.5, cells.\
(**A--C**) Cells electroporated with HCV replicon RNA (**A, C**) or infected with HCVcc (**B**) were treated with 5 μM CsA (**A, B**) or CypI (**C**) 4 hr later. After 48 hr, RNA was extracted and expression of IFN-β mRNA was evaluated by qRT-PCR. Data were normalised by GAPDH expression and are expressed as fold change compared to the DMSO vehicle-treated control. (**D-E**) CypI potency does not depend on IFN signalling. HCV replication in Huh7 cells, electroporated as described above, and treated with IFN-β (5 ng/mL) or CypI, in the presence or absence of the Jak/STAT inhibitor ruxolitinib (Rux). Rux treatment rescued HCV replication from IFN-β inhibition ([**D**]{.smallcaps}) but not from CypI (**E**). (**F**) CsA treatment induces expression of a subset of antiviral genes in HCV-replicating Huh7 cells. RNA expression of IFN-β, CCL2, MX1, RSAD2 IFIT2, ANKRD, CXCL2, CXCL10 and TNFα mRNA was evaluated by qRT-PCR at 48 hpe in Huh7 cells electroporated with HCV replicon RNA and treated with CsA (5 μM) at four hpe. Data were normalised by GAPDH expression and are expressed as fold change compared to the DMSO vehicle-treated control. All graphs show means ± standard deviation from at least three independent experiments each performed in triplicate. Statistical significance was evaluated by t-test using GraphPad Prism (\*\*\*\* p-value\<0.0001; \*\*\* p-value\<0.001; n.s. (not significant), p-value\>0.05). Detection limits of the assay ([D]{.smallcaps}) or gene expression in DMSO-treated cells (set as 1) (F) are shown by the dotted grey line.](elife-52237-fig4){#fig4}

We confirmed that induction of antiviral responses by CypI in Huh7 cells was specifically the result of HCV replication (rather than transfection of RNA into the cytoplasm) by comparison to a replication-defective replicon with a mutation in the polymerase active site ([@bib60]). Electroporation with either wild-type or replication-defective replicon RNA similarly resulted in translation of luciferase from the input RNA ([Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}) and induction of IFN-β expression at 4 hr post electroporation (hpe) ([Figure 4---figure supplement 1B](#fig4s1){ref-type="fig"}), reflecting initial transfection of RNA into the cytoplasm. By 24--48 hpe, however, no luciferase activity or IFN-β mRNA expression above the background level could be detected in cells electroporated with the replication-defective replicon ([Figure 4---figure supplement 1A--B](#fig4s1){ref-type="fig"}). Furthermore, the induction of IFN-β expression by CsA at 48 and 72 hpe was only observed in cells electroporated with the wild-type replicon ([Figure 4---figure supplement 1C--F](#fig4s1){ref-type="fig"}).

We next evaluated whether the CypI antiviral potency was dependent on increased IFN-β signalling. Addition of exogenous IFN-β inhibited HCV replication in Huh7 cells ([Figure 4D](#fig4){ref-type="fig"}), confirming that Huh7 cells are capable of responding to IFN. Although pharmacological inhibition of the Jak/STAT pathway by ruxolitinib treatment rescued HCV replication from inhibition by IFN-β ([Figure 4D](#fig4){ref-type="fig"}), ruxolitinib treatment had no effect on viral replication in the absence of exogenous IFN-β. Furthermore, ruxolitinib did not affect the potency of CsA ([Figure 4E](#fig4){ref-type="fig"}) or other CypI ([Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}) against HCV replication in Huh7 cells, suggesting that the antiviral effect is independent of IFN signalling. The notion that IFN was not required for maximal CypI activity was also supported by an experiment using anti-human interferon alpha/beta receptor chain two antibody (IFNAR) to inhibit IFN activity through receptor blockade. Anti-IFNAR treatment did not affect the potency of CsA against HCV but effectively rescued HCV replication from inhibition by IFN-β in a control experiment. ([Figure 4---figure supplement 3A--B](#fig4s3){ref-type="fig"}). The lack of a requirement for IFN in the effect of CypI is likely explained by direct induction of antiviral genes with inhibitory activity against HCV, here exemplified by viperin (*RSAD2*) ([@bib28]; [@bib67]), in Huh7 but not Huh7.5 cells ([Figure 4F](#fig4){ref-type="fig"}, [Figure 4---figure supplement 4](#fig4s4){ref-type="fig"}). Thus, we propose that in these experiments, CypI induces IFN-independent, cell-intrinsic antiviral immunity. However, in vivo, IFN induction would be expected to influence HCV replication and adaptive immune responses and thus the antiviral activity of CypI in patients.

CypI disrupt formation of the HCV replication organelle {#s2-4}
-------------------------------------------------------

We next sought to identify the mechanisms underlying the observed activation of antiviral genes. CypA has previously been implicated in formation of the HCV RO. Silencing of CypA expression by RNAi ([@bib12]) or treatment with a CsA analogue (cyclosporine D) ([@bib45]) inhibited formation of the double membrane vesicles (DMVs) that comprise the HCV RO, thus inhibiting HCV replication. We hypothesised a model in which 'uncloaking' of viral RNA, aided by disruption of the RO, and subsequent sensing of exposed cytosolic viral RNA, leads to IFN production in Huh7 cells. To test this model, we first evaluated whether our novel CypI inhibited formation of HCV-induced DMVs. As described previously, we used an NS3-5B expression construct to specifically evaluate DMV formation independently of viral RNA replication ([@bib45]; [@bib56]). Huh7-Lunet/T7 cells were transfected with the pTM-NS3-5B expression construct and treated with CypI 4 hr later. At 24 hr post-transfection, we evaluated NS5A expression and DMV formation. CypI treatment did not affect expression of NS5A as measured by immunofluorescence ([Figure 5A](#fig5){ref-type="fig"}) and western blot ([Figure 5B](#fig5){ref-type="fig"}). However, treatment with CsA, depsin or CsA-Prtc1 caused a significant reduction in the number and size of DMVs observed by transmission electron microscopy (TEM) in transfected cells ([Figure 5C--E](#fig5){ref-type="fig"}), suggesting incomplete and impaired formation of the RO.

![Antiviral CypI disrupt formation of the HCV replication organelle.\
(**A-E**) Huh7-Lunet/T7 cells were transfected with pTM_NS3-5B and treated with CypI (5X EC90) at 4 hours post-transfection. Transfection efficiency and NS5A expression were evaluated 24 hours later by immunofluorescence (**A**) or Western blot for NS5A (**B**). (**C**) Representative electron micrographs showing the effect of CypI treatment on DMV formation. (**D-E**) The number and size of DMVs in 3-7 different cells per condition were quantitated using ImageJ. Statistical significance was evaluated by t-test using GraphPad Prism (\* p-value \< 0.05; \*\* p-value \< 0.01; \*\*\* p-value \< 0.001).](elife-52237-fig5){#fig5}

RIG-I-like receptors and MAVS do not contribute to the antiviral potency of CypI {#s2-5}
--------------------------------------------------------------------------------

Given the proposed role of the RO in viral innate immune evasion, RO disruption may plausibly increase exposure of replicating viral RNA to innate immune sensors. We therefore sought to determine which sensors might contribute to detection of viral RNA in the presence of CypI. Huh7 cells are capable of responding to cytosolic RNA and initiating antiviral signalling through RIG-I, MAVS and IRF3 ([@bib63]; [@bib5]). However, Huh7.5 cells are less responsive, which may reflect a defect in RIG-I ([@bib63]). Therefore, we hypothesized that the active RIG-I pathway in Huh7 cells contributes to the antiviral signalling induced by CypI. We first evaluated the RIG-I-like receptors (RLRs), RIG-I and Mda5. We tested the activity of CypI against HCV replication in Huh7.5 cells stably expressing functional RIG-I, Mda5, or both RIG-I and Mda5. These reconstituted cell lines have been described previously and have restored RNA sensing of HCV ([@bib29]). However, stable expression of RIG-I or Mda5 (or both) had little, if any, effect on HCV replication at 48 hr ([Figure 6A](#fig6){ref-type="fig"}) and, more importantly, did not affect the antiviral potency of the CypI in Huh7.5 cells ([Figure 6B](#fig6){ref-type="fig"}). Similarly, transient transfection of RIG-I into Huh7.5 cells ([Figure 6---figure supplement 1A](#fig6s1){ref-type="fig"}) did not affect HCV replication ([Figure 6---figure supplement 1B](#fig6s1){ref-type="fig"}), consistent with previous findings ([@bib5]), or CypI potency ([Figure 6---figure supplement 1C](#fig6s1){ref-type="fig"}).

![The RLR/MAVS pathway does not contribute to the antiviral potency of CypI.\
Huh7.5 cells stably expressing RIG-I, Mda5 or both were electroporated with HCV replicon RNA and treated with increasing concentrations of CypI at four hpe. Replication was measured by luciferase activity at 48 hpe and is expressed as RLU (**A**) or percentage relative to the DMSO vehicle-treated control (**B**). Expression of RIG, Mda5 or both did not significantly affect HCV replication at 48 hr (**A**) or CypI dose-response curves in Huh7.5 cells (**B**). (**C**) Western blot detecting MAVS in single cell cloned Huh7 cells following MAVS knockout by CRISPR/Cas9. Huh7-sgMAVS cells were electroporated with 5 μg HCV replicon RNA in the presence or absence of plasmid encoding wild type MAVS (MAVS-WT) or mutant MAVS-C508R (conferring NS3/4A protease resistance). CypI were added at four hpe. Replication was measured by luciferase activity at 48 hpe and is expressed as RLU (**D**) or percentage relative to DMSO-treated control (**E**). HCV replication was not affected by knockout of MAVS (**D**) but was decreased by transfection of plasmid encoding MAVS-C508R (**E**). The presence or absence of MAVS did not affect the CypI dose response curves (F). (**F**) Huh7 or Huh7 MAVS KO cells were electroporated with HCV replicon RNA as described above, and treated with 5 μM CsA at four hpe. At 48 hpe, RNA was extracted and expression of *IFN-β* mRNA was evaluated by qRT-PCR. Data were normalised by GAPDH expression and is expressed as fold change compared to the DMSO vehicle-treated control. (**A-F**) All graphs show means ± standard deviation from at least three independent experiments each performed in triplicate. Statistical significance was evaluated by t-test using GraphPad Prism (n.s., not significant; p-value\>0.05).](elife-52237-fig6){#fig6}

Since MAVS is a key adaptor protein downstream of RIG-I and Mda5, we confirmed this observation in a loss-of-function context in Huh7 cells by generating clonal Huh7 MAVS knockout (KO) cell lines by CRISPR/Cas9 ([Figure 6C](#fig6){ref-type="fig"}). We evaluated HCV replication and CypI potency in MAVS KO Huh7 cells compared to control cells generated in the same manner with a non-targeting guide RNA. The loss of MAVS did not affect HCV replication evaluated compared to control cells ([Figure 6D](#fig6){ref-type="fig"}). However, exogenous expression of WT or HCV protease-resistant MAVS mutant C508R ([@bib38]) into MAVS KO Huh7 cells decreased viral replication ([Figure 6E](#fig6){ref-type="fig"}), likely due to induction of interferon responses ([@bib3]). This is consistent with the importance of MAVS and its cleavage by HCV protease in HCV replication. Crucially, the antiviral potency of CypI was unaffected by the absence of MAVS ([Figure 6F](#fig6){ref-type="fig"}), and transfection of the C508R protease-resistant MAVS into MAVS KO Huh7 cells also had no effect on CypI activity ([Figure 6F](#fig6){ref-type="fig"}). Furthermore, CypI still induced expression of IFN-β mRNA in HCV-replicating MAVS KO Huh7 cells ([Figure 6G](#fig6){ref-type="fig"}), indicating that CypI induction of IFN-β expression is not dependant on the RLR/MAVS pathway. It is worth noting that treatment with daclatasvir, an inhibitor that similarly blocks formation of the HCV RO ([@bib4]) and targets domain I of NS5A ([@bib24]), inhibits HCV replication without inducing IFN-β expression ([Figure 6---figure supplement 2A--B](#fig6s2){ref-type="fig"}). Therefore, sensing of viral RNA in the presence of CypI is likely not the result of simply 'uncloaking' by disruption of the RO but rather through a more complex CypA-dependent mechanism. Notably, NS5A domain II (where CypA binds) is dispensable for RO formation ([@bib57]) but is required to suppress IFN ([@bib29]) and control PKR ([@bib23]).

PKR modulates the antiviral potency of CypI against HCV {#s2-6}
-------------------------------------------------------

Given the documented role of the CypA target NS5A in binding and inhibiting PKR ([@bib22]) and the proposed role of CypA in regulating PKR activity ([@bib14]), we next evaluated a role for PKR in determining CypI potency against HCV. We first compared PKR expression and activation in HCV replicating Huh7 and Huh7.5 cells by western blot ([Figure 7A--B](#fig7){ref-type="fig"}). Importantly, PKR was more abundant in Huh7 cells, and, strikingly PKR T446 autophosphorylation (a marker of PKR activation) was observed in Huh7 but decreased in Huh7.5 cells ([Figure 7A](#fig7){ref-type="fig"}). We hypothesised that PKR may be impaired in sensing HCV RNA in Huh7.5 cells relative to the parental Huh7 cells. To test this hypothesis, we generated Huh7 PKR KO cell lines by CRISPR/Cas9 ([Figure 7C](#fig7){ref-type="fig"}) and evaluated the sensitivity of HCV to CypI inhibition in these cells. The antiviral potency of the CypI against HCV replication and HCVcc infection was markedly decreased ([Figure 7D--E](#fig7){ref-type="fig"}). These data are consistent with PKR contributing to CypI potency and confirm a role for PKR in the control of HCV replication. Importantly, CsA treatment failed to induce IFN-β mRNA expression in HCV-replicating PKR KO Huh7 cells ([Figure 7F](#fig7){ref-type="fig"}), further supporting the model in which induction of IFN, and anti-HCV restriction factors, is mediated through PKR in the presence of CypI. To confirm the role of PKR activity, we next tested CypI potency in Huh7 and Huh7.5 cells in the presence of the PKR inhibitor C16, which prevents PKR activation ([@bib31]). C16 decreased CsA potency in Huh7 cells, but not in Huh7 PKR KO cells ([Figure 7G](#fig7){ref-type="fig"}), and only minimally affected CsA potency against HCV in Huh7.5 cells ([Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}).

![PKR modulates the antiviral potency of CypI against HCV.\
(**A**) PKR expression and phosphorylation is reduced in Huh7.5 cells. Huh7 or Huh7.5 cells electroporated with in vitro transcribed HCV replicon RNA were lysed at 48 hpe, and PKR expression and phosphorylation assessed by western blot. One representative blot out of three independent experiments is shown. (**B**) Quantitation of band density from three independent experiments showing adjusted relative density normalised to the actin loading control. (**C**) Western blot detecting PKR expression in single cell cloned Huh7 cells following PKR knockout by CRISPR/Cas9. (**D**) CypI potency against HCV replication is decreased in the absence of PKR. Non targeted Huh7 (Huh7 (NT)) or Huh7 PKR KO clones 1 (c1) or 4 (c4) were electroporated with in vitro transcribed HCV replicon RNA and CypI added at four hpe. Replication was measured by luciferase activity at 48 hpe and is expressed as percentage relative to DMSO-treated control. (**E**) Huh7 NT or PKR KO cells clone 4 (c4) were infected with HCVcc and treated with increasing concentrations of CypI at four hpi. Replication was measured by luciferase activity after 72 hr and is expressed as percentage relative to DMSO-treated control. (**F**) Huh7 NT or PKR KO cells were electroporated with HCV replicon RNA or infected with HCVcc, and treated with 5 μM CsA at four hpe. At 48 hpe, RNA was extracted and expression of *IFN-β* mRNA was evaluated by qRT-PCR. Data were normalised by GAPDH expression and is expressed as fold change compared to the DMSO vehicle-treated control. (**G**) Huh7 or Huh7 PKR KO cells were electroporated as described above, and at four hpe were treated with increasing concentrations of CsA in the presence or absence of the PKR inhibitor C16 (1 μM). C16 decreased CypI potency in Huh7 cells, but not in Huh7 PKR KO cells. (**A-F**) All graphs show means ± standard deviation from at least three independent experiments each performed in triplicate. Statistical significance was evaluated by t-test using GraphPad Prism (\*\*\*\* p-value\<0.0001; \*\*\* p-value\<0.001; \*\* p-value\<0.005). Gene expression in DMSO-treated cells (set as 1) (F) shown by the dotted grey line.](elife-52237-fig7){#fig7}

We also sought to confirm the role of PKR in CypI activity by over-expressing PKR in Huh7 PKR knockout cells. However, PKR over-expression in itself led to PKR activation, as evidenced by its autophosphorylation ([Figure 7---figure supplement 2A](#fig7s2){ref-type="fig"}). Concordantly, PKR over-expression had antiviral activity ([Figure 7---figure supplement 2B](#fig7s2){ref-type="fig"}) but this did not impact CsA sensitivity ([Figure 7---figure supplement 2C](#fig7s2){ref-type="fig"}), presumably because the PKR antiviral effect in this experiment is mediated through activation by phosphorylation and suppression of translation. This is consistent with previous observations of translation shutdown on PKR over-expression ([@bib26]; [@bib2]; [@bib13]; [@bib66]).

We next tested whether the absence of PKR broadly affects the sensitivity of HCV to the antiviral activity of telaprevir (NS3/4A protease inhibitor) and daclatasvir (NS5A inhibitor) in Huh7 and Huh7 PKR KO cells. Unlike Cyp inhibition ([Figure 7D--E](#fig7){ref-type="fig"}), the absence of PKR did not affect the inhibitory activity of telaprevir or daclatasvir ([Figure 7---figure supplement 3](#fig7s3){ref-type="fig"}). Collectively, these data are consistent with a specific role for PKR in the enhanced antiviral activity of CypI in Huh7 cells.

CypI treatment induces PKR- and IRF1-dependent cell-intrinsic antiviral responses {#s2-7}
---------------------------------------------------------------------------------

The most well characterised function of PKR is inhibition of RNA translation, which requires PKR autophosphorylation to activate its kinase activity leading to eIF2α phosphorylation. CypI have previously been shown to inhibit PKR autophosphorylation, thus preventing eIF2α phosphorylation by PKR ([@bib14]; [@bib7]), which was proposed to restore expression of ISGs at the protein level to contribute to the antiviral effect ([@bib14]). Consistently, we observed that our CypI inhibited PKR autophosphorylation in HCV-replicating cells ([Figure 8---figure supplement 1A](#fig8s1){ref-type="fig"}) while only minimally affecting PKR expression based on densitometry analysis ([Figure 8---figure supplement 1B--C](#fig8s1){ref-type="fig"}). However, our observation that CypI treatment induces PKR-dependent expression of IFN-β mRNA in HCV-replicating or HCV-infected cells ([Figure 4A--C](#fig4){ref-type="fig"}, [Figure 7F](#fig7){ref-type="fig"}) suggests the involvement of additional transcriptional mechanisms.

PKR activates inflammatory transcription factors NF-κB and IRF1 directly and this is thought to be independent of its kinase activity, at least in the case of NF-κB activation ([@bib8]; [@bib9]). Interestingly, CsA predominantly induced expression of IRF1 target genes, and not canonical NF-κB targets ([@bib72]; [Figure 4F](#fig4){ref-type="fig"}), and this induction was PKR-dependent in both HCV-replicating ([Figure 8A](#fig8){ref-type="fig"}) and HCVcc-infected cells ([Figure 8B](#fig8){ref-type="fig"}). Thus, restriction of HCV replication by CypI depends on the PKR-mediated induction of antiviral gene expression, including IRF1 targets. Notably, IRF1 and several IRF1 target genes have been shown to negatively regulate HCV replication ([@bib32]; [@bib72]), such as *RSAD2* (viperin) ([@bib28]; [@bib67]). Unlike CsA, CsA-Prtc1 treatment did not induce expression of IRF1 target genes ([Figure 8---figure supplement 2](#fig8s2){ref-type="fig"}), consistent with our earlier findings evaluating IFN-β expression ([Figure 4C](#fig4){ref-type="fig"}). Importantly, CsA treatment did not induce expression of these genes in the Huh7.5 cells, which we propose are defective for PKR function ([Figure 4---figure supplement 4](#fig4s4){ref-type="fig"}).

![PKR induces IRF1-dependent intrinsic antiviral responses in HCV-replicating CypI-treated Huh7 cells.\
(**A--B**) Induction of IRF1 target gene expression in HCV-replicating (**A**) or HCV-infected (**B**) cells depends on PKR. Expression of *IFN-β, CCL2, MX1* or *RSAD2* mRNA was evaluated by qRT-PCR at 48 hpe in Huh7 NT, or PKR KO cells, electroporated with HCV replicon RNA or infected with HCVcc and treated with 5 μM CsA at four hpe. Data were normalised by GAPDH expression and are expressed as fold change compared to the DMSO vehicle-treated control. (**C**) Western blot detecting IRF1 in Huh7 cells following IRF1 knockout by CRISPR/Cas9 and single cell cloning. (**D**) CypI potency against HCV replication was decreased in the absence of IRF1. HCV replication in Huh7 NT or IRF1 KO cells, measured by luciferase activity at 48 hpe, after CypI addition at four hpe, expressed as percentage relative to DMSO-treated control. (**A-D**) All graphs show means ± standard deviation from two or three independent experiments each performed in triplicate. Gene expression in DMSO-treated cells (set as 1) (A--B) is shown by the dotted grey line.](elife-52237-fig8){#fig8}

To confirm the involvement of IRF1, we generated Huh7 IRF1 KO cell lines by CRISPR/Cas9 ([Figure 8C](#fig8){ref-type="fig"}) and tested the effect of CypI against HCV replication in these cells. Strikingly, the antiviral potency of the CypI against HCV replication was markedly decreased in the IRF1 KO cells ([Figure 8D](#fig8){ref-type="fig"}). Importantly, the effect of IRF1 KO closely matched the phenotype we observed in the PKR KO cells ([Figure 7D](#fig7){ref-type="fig"}). Collectively, these findings demonstrate that PKR signalling through IRF1 determines the potency of CypI against HCV.

Discussion {#s3}
==========

CypA is a critical host factor for many viruses, although the mechanisms underlying its remarkably broad usage as a viral host factor remain unclear. One intriguing possibility is that viruses recruit CypA to evade host antiviral responses, evidenced by recent studies implicating CypA in viral innate immune evasion ([@bib55]) and in regulation of innate immune signalling ([@bib64]; [@bib42]). Therefore, CypA is an exciting target for broadly-acting antiviral intervention based on disrupting viral evasion and harnessing host intrinsic antiviral responses to combat infection. Given that CypA was linked with HCV immune evasion in patients ([@bib30]), we sought to understand the potential mechanisms in the context of HCV infection. We found that CypA is crucial for HCV evasion of PKR-dependent, but not RLR/MAVS-dependent, antiviral responses. Furthermore, our results suggest that a deficiency in PKR-dependent responses, as well as defective RIG-I ([@bib63]), may contribute to Huh7.5 cell permissivity for HCV replication, which is consistent with previous observations showing that RIG-I does not play a role ([@bib5]). Indeed, differences in permissivity between Huh7 and Huh7.5 cells are likely governed by a combination of factors, including RIG-I ([@bib63]) and CD81 ([@bib36]), among others. Overall, our findings: (a) clarify the role of Cyps in HCV replication, (b) provide mechanistic insight into PKR activity and regulation, and (c) contribute to understanding the broad exploitation of CypA by viruses, opening perspectives for broadly acting antiviral therapies based on disrupting CypA-mediated viral evasion.

Clarifying the roles of Cyps in HCV replication {#s3-1}
-----------------------------------------------

While Cyps are clearly involved in HCV replication, the respective roles of Cyp family members have been disputed ([@bib70]; [@bib73]). Although binding of CypB to the HCV RNA-dependent RNA polymerase (NS5B) was suggested to be important for HCV RNA replication ([@bib70]), the interaction of CypA with the intrinsically unstructured domain II of HCV NS5A ([@bib27]; [@bib20]) was also shown to be required for HCV replication and infection ([@bib73]; [@bib33]; [@bib11]; [@bib41]).Furthermore, CypA and CypB both bind to proline residues within the unstructured domain II of NS5A ([@bib27]; [@bib20]), which also interacts with the HCV polymerase NS5B ([@bib49]). Here, our data support a direct role for CypB in HCV RNA replication ([@bib70]), which is consistent with it being equally required in Huh7 and Huh7.5 cells ([Figure 1C](#fig1){ref-type="fig"}). In contrast, the requirement for CypA varies according to cell line and appears to be important for evasion of host antiviral responses in innate sensing competent cells (i.e., Huh7) ([Figure 1C](#fig1){ref-type="fig"}).

We propose a model where CypB forms a complex with NS5A and NS5B to directly regulate HCV RNA replication, while CypA forms a complex with NS5A and PKR, leading to inhibition of PKR-dependent antiviral responses ([Figure 9](#fig9){ref-type="fig"}). CypI, which target both CypA and CypB ([@bib15]), directly inhibit HCV replication in both Huh7 and Huh7.5 cells by targeting CypB, and they disrupt the CypA-NS5A interaction, thus rendering them more efficacious in Huh7 cells because there they relieve NS5A inhibition of PKR and restore PKR-dependent antiviral responses. Notably, a differential requirement for CypA in Huh7-Lunet and Huh7.5 cells has also been observed for replication of genotype 1b (Con1) and genotype 2a (JFH-1) replicons ([@bib33]), suggesting that these mechanisms are consistent across HCV genotypes.

![Working model for the proposed roles of Cyps in HCV replication, and the proposed antiviral mechanisms of CypI against HCV.](elife-52237-fig9){#fig9}

CypA has been proposed to have a role in HCV assembly ([@bib46]; [@bib1]), which is likely reflected by our observation that CypA depletion in Huh7.5 cells decreased HCVcc infection ([Figure 1F](#fig1){ref-type="fig"}), but not replication of the HCV replicon ([Figure 1C](#fig1){ref-type="fig"}). This is consistent with previous studies showing a large decrease in HCVcc infection in Huh7.5 cells silenced for CypA expression ([@bib25]).

Mechanistic insight into PKR-dependent antiviral responses {#s3-2}
----------------------------------------------------------

NS5A is key for HCV evasion of innate antiviral responses ([@bib45]; [@bib37]; [@bib51]), including those dependent on PKR ([@bib22]; [@bib23]; [@bib53]). Our data suggest that CypA is required for HCV evasion of PKR-mediated antiviral responses ([Figure 8A--B](#fig8){ref-type="fig"}) that involve IRF1 signalling ([Figure 4F](#fig4){ref-type="fig"}). Upon activation by dsRNA binding or cellular stress ([@bib71]), PKR activates IRF1 ([@bib35]), and IRF1 was recently shown to drive intrinsic hepatocyte resistance to positive-sense RNA viruses (including HCV and other *Flaviviridae*) ([@bib72]). Furthermore, IRF1 exerted the most potent inhibition out of 380 ISGs screened against four positive-sense RNA viruses (including HCV, *Flaviviridae* and *Togaviridae*) ([@bib62]). Consistent with our observations ([Figure 7B--C](#fig7){ref-type="fig"}), the antiviral activity of IRF1 was independent of canonical Jak-STAT IFN signalling ([@bib62]), suggesting that IRF1 controls a unique IFN-independent antiviral program that is key for antiviral defense in hepatocytes ([@bib72]). HCV efficiently controls NF-κB ([@bib37]; [@bib51]) and MAVS ([@bib38]), but appears to be more sensitive to IRF1 restriction ([@bib72]). We propose that the ability of HCV to inhibit PKR and evade downstream IRF1 responses depends critically on the CypA-NS5A interaction, and that disruption of this interaction by CypI leads to activation of PKR and engages IRF1-dependent antiviral responses.

CypA has been proposed as a regulator of PKR activity in the context of eIF2α phosphorylation ([@bib14]). Our data suggest that CypA is required for regulation of PKR in a broader context, including activation of IRF1, since targeting CypA for proteolytic degradation by PROTAC (e.g. CsA-Prtc1) blocked the activation of IFN-β or IRF1 target gene expression that we observed with CsA ([Figure 4C](#fig4){ref-type="fig"}, [Figure 8---figure supplement 2](#fig8s2){ref-type="fig"}). In contrast to CsA-Prtc1, CsA disrupts CypA interactions and therefore affects complex formation, but does not cause CypA degradation. Given that CypA regulates protein complexes and that CypA, NS5A and PKR have all been shown to interact ([@bib27]; [@bib14]; [@bib23]), CypA-NS5A-PKR complex formation likely regulates PKR activation in HCV-replicating cells. Our data suggest that perturbation of the complex by CypI disrupts NS5A inhibition of PKR, but not PKR activation of IRF1.

The regulation of PKR is not fully understood ([@bib10]), and the mechanisms by which PKR activates NF-κB and IRF1 in particular are unclear, although appear to be independent of PKR kinase activity, at least in the case of NF-κB ([@bib8]; [@bib9]). Our data suggest that activation of IRF1 by PKR does not require canonical PKR activation mechanisms (i.e. autophosphorylation), as CypI inhibit PKR autophosphorylation in HCV-replicating cells ([Figure 8---figure supplement 1](#fig8s1){ref-type="fig"}) but still induce PKR-dependent activation of antiviral target genes ([Figure 8A--B](#fig8){ref-type="fig"}) regulated by IRF1 and potentially other transcription factors, suggesting distinct mechanisms of PKR activation and downstream signalling.

A novel antiviral mechanism {#s3-3}
---------------------------

Using HCV as a model, we have discovered that CypI restore PKR-dependent antiviral responses to inhibit infection. This represents a novel and potentially broadly acting antiviral mechanism based on inhibition of viral evasion and restoration of host intrinsic antiviral immunity. Whether other viruses exploit the CypA-PKR interaction to evade antiviral immunity remains to be determined, although many viruses do require CypA ([@bib16]), including medically important (and currently untreatable) human viruses such as *Flaviviridae* and *Coronaviridae* family members ([@bib54]; [@bib17]; [@bib52]). Many viruses also encode PKR antagonists, although the roles of CypA in viral PKR antagonism (beyond our current study) have not yet been elucidated.

Overall, CypA is an attractive antiviral target for a broad array of viruses, including emerging human viruses currently lacking specific antiviral therapies. Here, we contribute to the understanding of CypA-HCV interactions and PKR activation, opening perspectives for the further development of CypA-targeting broadly acting antivirals against untreatable human viruses.

Materials and methods {#s4}
=====================

Cell lines {#s4-1}
----------

Huh7 and Huh7.5 cells were kindly provided by Dr. Joe Grove (UCL). Huh7 cells were originally obtained from Dr. Yoshiharu Matsuura (from Japanese Collection of Research Bioresources Cell Bank, JCRB0403). Huh7.5 cells were obtained from Apath LLC (APC166). Huh7, Huh7.5 and 293 T cells were cultured in DMEM supplemented with 10% FBS, 50 U/mL penicillin and 50 μg/mL streptomycin at 37°C in 5% CO~2~. Huh7-Lunet/T7 cells ([@bib21]) were cultured in the presence of 5 μg/mL Zeocin. Cells routinely tested negative for mycoplasma using the Lonza MycoAlert mycoplasma detection kit.

Inhibitors {#s4-2}
----------

Synthesis of the novel CypI is described in [Supplementary file 1](#supp1){ref-type="supplementary-material"}. CypI were resuspended in dimethyl sulfoxide (DMSO, Sigma-Aldrich) as 10 mM stocks. CypI were diluted in DMEM-10% FBS at the indicated concentrations and added to cells at 4 hr post-electroporation unless otherwise indicated. The PKR inhibitor C16 was obtained from Sigma-Aldrich (I9785). Ruxolitinib was obtained from Cell Guidance Systems. Telaprevir (VX-950) was obtained from Generon/Adooq Bioscience (A10902-2). Daclatasvir (BMS-790052) was obtained from Insight Biotechnology (D101505).

Antibodies {#s4-3}
----------

Mouse monoclonal anti-NS5A antibody (9E10) was kindly provided by Dr. Joe Grove (UCL) and has previously been described ([@bib39]). Antibodies against β-actin (Abcam; ab8226 or ab8227), CypA (Enzo; BML-SA296-0100), CypB (Abcam; ab16045), CypD (Abcam; ab110324), RIG-I (Cell Signaling Technology; \#3743) MAVS (Santa Cruz Biotechnology; sc166583), PKR (Abcam; ab32052) and phospho-PKR T446 (Abcam; ab32036) were also used. Secondary IRDye 680- or 800-labelled antibodies and AlexaFluor-conjugated antibodies were obtained from LI-COR Biosciences or Thermo Scientific, respectively. Anti-human interferon alpha/beta receptor chain two antibody (IFNAR2) (Pbl Assay Science, 21385--1) and an IgG2A control antibody (R and D Systems, 4460 MG-100) were used at 2 μg/mL.

Plasmids {#s4-4}
--------

The subgenomic reporter replicon pFKI389Luc/NS3-3'\_dg_JFH (HCV SGR) and replication deficient mutant with a deletion in the NS5B active site (ΔGDD) have been described previously ([@bib60]). The plasmid J6/JFHRluc2 (HCVcc) was kindly provided by Dr. Joe Grove (UCL) with permission from Apath LLC. The HCV polyprotein expression construct pTM_NS3-5B has been described previously ([@bib56]). LentiCRISPRv2 was a gift from Dr. Feng Zhang (Addgene plasmid \#52961). For knockout of specific genes, synthetic oligos ([Supplementary file 2](#supp2){ref-type="supplementary-material"}) were cloned into LentiCRISPRv2 as described ([@bib59]). The lentiviral PKR expression plasmid (pSCRPSY-EIF2AK) ([@bib18]) was a kind gift from Dr. Sam Wilson (University of Glasgow).

In vitro transcription and electroporation of RNA {#s4-5}
-------------------------------------------------

Plasmid DNA (10 μg) was linearised by digestion with MluI (HCV SGR) or XbaI (HCVcc). Purified linearised DNA (1 μg) was used as a template for in vitro transcription according to the T7 MEGAscript Kit instructions (Ambion, Life Technologies). RNA was resuspended in nuclease-free water at a concentration of 1 μg/μL, aliquoted and stored at −80°C. HCV SGR RNA (5 μg) or HCVcc RNA (10 μg) was electroporated into 2 × 10^6^ cells or 4 × 10^6^ target cells, respectively, using either a Neon transfection system (Thermo Scientific) or Amaxa nucleofector (Lonza). In both cases, single-cell suspensions were washed with PBS and resuspended in 100 μL of Buffer R (Neon) or Nucleofector Solution T (Amaxa), respectively. Resuspended cells were mixed with RNA and loaded into a Neon Tip or Amaxa cuvette. Cells were electroporated using the Neon Transfection system (1400 V, 20 ms, one pulse) or the Amaxa Nucleofector system (program T-016) and resuspended in DMEM-10% FBS prior to seeding in 96-well plates at a density of \~2×10^4^ cells/well. For experiments using IFNAR2 antibody, electroporated cells were plated at \~7.5×10^3^ cells/well.

Preparation of virus stocks {#s4-6}
---------------------------

In vitro transcribed RNA (10 μg), generated as described above, was electroporated into 4 × 10^6^ Huh7.5 cells. Electroporated cells were plated into 6-well plates, and were split and expanded as necessary. Supernatants containing HCVcc were collected on days 3 and 7, and filtered through a 0.45 μm syringe filter.

Lentivirus production and generation of stable cell lines {#s4-7}
---------------------------------------------------------

HEK293T cells plated in 10 cm dishes were transfected with 1 μg packaging plasmid p8.91 ([@bib77]), 1 μg envelope plasmid pMDG encoding VSV-G protein ([@bib47]) and 1.5 μg of transfer plasmid pHIV-SIREN ([@bib61]) encoding shRNA or lentiCRISPRv2 ([@bib59]) encoding sgRNA or pSCRPSY-EIF2AK2 lentiviral plasmid encoding PKR ([@bib18]) using Fugene-6 transfection reagent (Promega) as described ([@bib19]). Lentivirus supernatants were collected at 48 hr and 72 hr post-transfection and clarified by filtration through 0.45 μm syringe filters. Huh7 or Huh7.5 cells were plated in 6-well plates at a density of 2.5 × 10^5^ cells/well prior to being transduced with 1 mL/well of lentivirus supernatant in the presence of 8 μg/mL polybrene. Transduced cells were selected by addition of 2.5 μg/mL puromycin at 72 hr post-transduction. Alternatively, to generate CRISPR knockout cells without genome integration of Cas9, the lentiCRISPRv2 plasmid (2.5 μg) was electroporated into Huh7 or Huh7.5 cells (5 × 10^5^ cells) using the Neon electroporator as described above. Electroporated cells were plated in 10 cm^2^ dishes and selected by addition of 2.5 μg/mL puromycin at 24 hr post-electroporation. After 72 hr of puromycin selection, single cell clones were isolated by limiting dilution in 96-well plates. Loss of target protein expression was confirmed by western blot.

Site-directed mutagenesis {#s4-8}
-------------------------

The HCV NS5A D316E/Y317N mutant ([@bib74]) was generated in the subgenomic replicon using a modified version of the Q5 Site-Directed Mutagenesis Protocol (New England BioLabs). The PCR reaction was assembled according to the protocol, using mutagenic primers (for oligos see [Supplementary file 2](#supp2){ref-type="supplementary-material"}). PCR product (4 μL) was used in the subsequent kinase-ligase-Dpn1 reaction, following which 5 μL of ligation product was transformed into chemically competent *E. coli* (strain HB101). The mutation was confirmed by sequencing using an NS5A forward primer ([Supplementary file 2](#supp2){ref-type="supplementary-material"}). The MAVS C508R mutation conferring NS3/4A protease resistance ([@bib38]) was generated using a modified version of the QuikChange II Site-Directed Mutagenesis (Agilent) protocol. The PCR was assembled using the MAVS-WT plasmid (50 ng) as template with *Pfu* Ultra High Fidelity polymerase (Agilent) and the mutagenic primers ([Supplementary file 2](#supp2){ref-type="supplementary-material"}). The PCR product was incubated with DpnI restriction enzyme (10 U/μL) at 37°C for 1 hr and then transformed into *E.coli* HB101. The mutation was confirmed by sequencing using a CMV forward primer ([Supplementary file 2](#supp2){ref-type="supplementary-material"}).

Luciferase measurement {#s4-9}
----------------------

Firefly luciferase activity was measured using the SteadyGlo reagent according to the manufacturer instructions (Promega). For measurement of Renilla luciferase activity, cells were washed once with PBS and then lysed with 50 μL/well of 1X passive lysis buffer (Promega). Lysates (20 μL) were transferred to 96-well white plates and Renilla activity was measured following addition of 50 μL of 2 μg/mL coelenterazine (NanoLight).

Transmission electron microscopy {#s4-10}
--------------------------------

Huh7-Lunet/T7 cells were seeded onto glass coverslips at a density of 1 × 10^5^ cells/well. Cells were transfected 24 hr later with the pTM_NS3-5B polyprotein expression construct using the TransIT LT1 transfection reagent (Mirus Bio LLC, Madison, WI). After 4 hr, cells were treated with DMSO or CypI (at 5X EC~90~, corresponding to 5 μM for CsA, 2 μM for depsin and 1 μM for CsA-Prtc1) until fixation 21 hr later. Cells were fixed for 30 min at room temperature with 2.5% glutaraldehyde in 50 mM sodium cacodylate (caco) buffer (pH 7.2) containing 10 mM MgCl~2~, 10 mM CaCl~2~, 100 mM KCl and 2% sucrose. Following washes with 50 mM caco buffer, cells were incubated with 2% osmium tetroxide in caco buffer for 40 min on ice. Samples were then washed with distilled water and incubated in 0.5% uranyl acetate overnight at 4°C. Samples were then washed with distilled water, and dehydrated by sequential incubation with increasing concentrations of ethanol (40%, 50%, 60%, 70%, 80%, 95%, 100%). Dehydrated samples were embedded in araldite-Epon (Araldite 502/Embed 812 kit, Electron Microscopy Sciences) and polymerized for 2 days at 60°C. Embedded cells were then cut into 70 nm thin sections (Leica Ultracut UCT microtome) and mounted onto a mesh grid. Sections were contrasted by incubation with 3% uranyl acetate in 70% methanol for 5 min, followed by incubation with 2% lead citrate in distilled water for 2 min. Finally, sections were visualised using a JEOL JEM1400 transmission electron microscope (JEOL Ltd., Tokyo, Japan) in the Electron Microscopy Core Facility at Heidelberg University. Images were analysed and double membrane vesicles were counted using ImageJ.

Immunofluorescence {#s4-11}
------------------

Huh7-Lunet/T7 cells seeded onto glass coverslips at a density of 1 × 10^5^ cells/well were fixed in 4% paraformaldehyde and then washed three times with PBS. Cells were then incubated with NS5A-specific monoclonal antibody (9E10) diluted 1:1000 in PBS containing 1% FBS and 0.5% Triton X-100. After overnight incubation at 4°C, cells were washed and secondary donkey anti-mouse AlexaFluor-488 antibody was added. Nuclear DNA was detected by DAPI staining. After incubation at room temperature for 1 hr, coverslips were washed, mounted on slides with FluoromountG and sealed with clear nail polish and imaged using a Nikon Eclipse Ti with 10x objective.

qRT-PCR {#s4-12}
-------

Cellular RNA was extracted using the RNeasy Mini kit (Qiagen) according to the manufacturer instructions. Recovered RNA was quantitated by Nanodrop and 500 ng of RNA was used to synthesize cDNA following the Superscript III Reverse Transcriptase protocol (Invitrogen). The resulting cDNA was diluted 1:5 in nuclease-free water prior to quantitative PCR (qPCR) using the FastSYBR Green Master Mix (Applied Biosciences). Reactions contained 5 μL 2X FastSYBR Green master mix, 2 μL diluted cDNA, 1 μL forward primer, 1 μL reverse primer and 1 μL nuclease-free water. Expression of IFN-β, ISGs and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was determined using specific primers (primer details in Table S1). Following normalisation to GAPDH expression, IFN-β or ISG expression was calculated as fold increase relative to DMSO-treated cells.

Western blot {#s4-13}
------------

Cells were resuspended in cell lysis buffer (50 mM Tris pH8, 150 mM NaCl, 1 mM EDTA, 10% glycerol, 1% Triton X-100% and 0.05% NP40). Cell lysates were incubated on ice for 30 min, followed by centrifugation at 14,000 rpm at 4°C for 15 min. Samples were diluted in 4X SDS-PAGE loading buffer (200 mM Tris pH 6.8, 8% SDS, 0.4% bromophenol blue, 40% glycerol and 2% β-mercaptoethanol), heated at 95°C for 5 min, and loaded onto 10% or 15% polyacrylamide-SDS gels. Following electrophoresis, proteins were transferred to a nitrocellulose membrane using the Bio-Rad TransBlot Turbo system according to the manufacturer instructions. Membranes were blocked in 5% milk diluted in Tris-buffered saline (TBS) with 0.5% Tween (TBS-T) for 1 hr prior to incubation with primary antibodies diluted in blocking solution overnight at 4°C. Membranes were washed extensively in TBS-T prior to incubation for 1 hr at room temperature with IRDye 800-labelled or IRDye 680-labeled antibodies diluted 1:10,000 in blocking solution. Membranes were washed extensively in TBS-T followed by washes in TBS (without Tween) and then scanned using an Odyssey Infrared imaging System (LI-COR Biosciences). Alternatively, membranes were incubated with horseradish peroxidase-conjugated mouse-specific secondary antibodies (Sigma-Aldrich, St. Louis, MO) diluted 1:10,000, prior to detection with the Western Lightning Plus-ECL reagent (Perkin-Elmer, Waltham, MA) and the Intas Science imager. Where indicated, densitometry analyses were performed using ImageJ and expressed as adjusted band density (normalized to actin loading control).

Cell viability assay {#s4-14}
--------------------

Huh7 or Huh7.5 cells were seeded in 96-well plates at a density of 1 × 10^4^ cells/well prior to being treated with serially diluted CypI. After 48 hr, cell viability was assessed using the alamarBlue Cell Viability Assay (ThermoScientific) according to the manufacturer instructions. Absorbance was measured using a microplate reader (Multiskan FC Microplate reader, Thermo Scientific) at 570 nM with a reference measurement at 595 nm.
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In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

**Acceptance summary:**

This study provides fundamental insight into the role of cyclophilins in hepatitis C virus replication and infection. The impact of this study is a deeper understanding of how cyclophilins function as co-factors during viral replication, and how cyclophilin inhibitors can confer antiviral effects through a new mechanism involving a cell intrinsic antiviral pathway.

**Decision letter after peer review:**

Thank you for submitting your article \"Hepatitis C virus exploits cyclophilin A to evade PKR\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by Päivi Ojala as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Thomas Pietschmann (Reviewer \#2).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

In this study, Colpitts et al. provide a broad and molecularly deep study analyzing the role of cyclophilins in hepatitis C virus replication and infection. They used cyclophilin inhibitors to provide evidence that hepatitis C virus co-opts cyclophilin A in order to evade an antiviral restriction pathway dominated by a PKR-IRF1 pathway. They provide additional data indicating that the observed phenotype is independent of RLH/MAVS-induced interferon pathways. The impact of this study is a deeper understanding of how cyclophilins function as co-factors during viral replication, and how Cyp inhibitors can confer antiviral effects through a new mechanism involving a cell intrinsic antiviral pathway.

Essential revisions:

Below are compiled comments from the three reviewers, each one numbered by general topic. The reviewers have requested that additional experiments be performed to address \#1-3, and possibly \#4, whereas point \#5 can likely be addressed without new experimentation.

1\) Studies related to further characterizing PKR KO phenotype:

a\) (Reviewer \#1) The Huh7 PKR KO phenotype with respect to viral replication is quite modest. If PKR is a major contributor to the permissivity differences between Huh7 and Huh7.5, then KO of PKR in Huh7.5 cells should have little effect on virus. This would be a good control to include. Along these lines, what is the impact of PKR KO on virus production? A concern is that these modest effects on HCV-luciferase RLU are not likely to have a major effect on virus production. Lastly, can the PKR KO effect be re-constituted with CRISPR-resistant PKR? Does ectopic expression of PKR in Huh7.5 cells make them more Huh7-like?

b\) (Reviewer \#2) The strongest and most direct piece of evidence supporting the conclusion that HCV uses CypA to evade PKR-dependent antiviral defences rests on Figure 6 and the use of two PKR knock out clones. The presented data show that HCV replication in the two PKR knock out clones is somewhat more resistant to inhibition by CypIs. Concomitantly, the authors show that mRNA induction of IFN-β by HCV is blunted in the PKR KO clones. In the same figure the authors show that a PKR inhibitor decreases the potency of a CypI in parental Huh7 cells but not so much in Huh-7.5 cells (in a previous figure the authors had shown a greater dependence of HCV on CypA in Huh7 compared to Huh-7.5 cells).

Given the high importance of these data for the main conclusion of the manuscript, in my view the authors should consider cell clonal effects, which potentially could confound this important observation. To this end, the authors could restore PKR expression in the knock out clones. One would expect restoration of HCV sensitivity towards CypIs as well as restoration of antiviral signalling. This would lend further support to the role of CypA in modulation PKR functioning and in turn HCV replication.

Alternatively/in addition, the authors could over-express PKR in Huh7 cells and explore if this enhances sensitivity to CypIs and also antiviral signalling. Taken together such experiments will extend the foundation of this important conclusion.

Along similar lines, the experiment displayed in Figure 6G should also include the comparison between Huh7 cells and the Huh7 PKR knock out clones. In support of the model proposed by the authors, one would think that the PKR inhibitor only shifts HCV sensitivity to CypIs in the Huh7 cells expressing functional PKR but not in the knock out clones. Again, this enhances the experimental foundation for the key conclusion of this paper.

Related to the same Figure 6, the authors should explore if the PKR knock out clones selectively display altered HCV susceptibility to CypIs and not globally to antivirals targeting HCV by different mechanisms (e.g. protease inhibitor, NS5A inhibitor, polymerase inhibitor). While a broad spectrum of different CypIs is already shown in the figure, the authors should consider adding data showing other HCV antivirals.

2\) Studies related to the conclusion that RLR-MAVS-IFN does not contribute to phenotype:

a\) (Reviewer \#1) Much of Figure 3 is dedicated to showing that induction of IFN-β correlates to CypI potency in Huh7, but not Huh7.5 cells. In Figure 6, the authors state that IFN-β induction in the presence of CypI is mediated by PKR. Then in Figure 7, the authors make the case that the IFN-β induction is actually not important (based on ruxolitinib experiments), but that antiviral gene expression through a PKR-IRF1 axis is the key pathway.

The layout of this story was a bit confusing. If IFN-β ends up having no role in the antiviral activity of CypI, why not put this out there up front in Figure 3? This would make the story more clear. That said, the authors should solidify this claim with IFNAR or STAT1 KO cells as genetic proof that IFN-β has no role. Testing IFN-dependent, but IRF1-independent ISG induction would also be a compelling control. Further, if IFN-β has no role here, then IFN bioassays (i.e., transferring soups and testing for inhibition of IFN-sensitive virus like VSV) would further bolster the claim.

b\) (Reviewer \#2) Exclusion that RLR/MAVS-dependent antiviral responses do not play a role is one major conclusion of this study. Therefore, it seems worthwhile to confirm the unresponsiveness of the cells employed here (and published previously) to RLR/MAVS-dependent viral danger signals.

c\) (Reviewer \#3) The authors provide data suggesting that CypI induced antiviral signaling is not dependent on RIGI and MAVS. Important controls would be to show that known RLH agonist actually trigger this pathway in their cells, i.e. the cells are signaling competent.

3\) Studies related to HCV genotype:

(Reviewer \#3) It has been previously been shown that non-JFH1 gts (e.g. Con1) maybe more sensitive to CypA depletion even in Huh7.5 cells. Thus, it would be important to confirm some of the critical data presented here with non-JFH1 based replicons.

4\) Concern about the claim that this mechanism is broadly applicable to other viruses:

(Reviewer \#3) The authors argue that one of the premises of their study was to investigate the role of CypA for other non-HIV viruses. HCV is arguably a very good example as its dependency on CypA is well established. However, based on the data presented here it is unclear how generalizable CypA-targeted therapies that affect host intrinsic antiviral responses to combat other (RNA) virus infections are. Either additional data are presented to show effects on other viruses or the statements in the manuscript (e.g. Introduction, last paragraph) should be limited to HCV.

5\) Additional major concerns that may be addressable without new experimentation:

a\) (Reviewer \#2) I was somewhat confused by the authors Discussion related to the differential relevance of CypB and A for HCV infection (subsection "Clarifying the roles of Cyps in HCV replication"). In brief, based on which evidence can the authors conclude that CypA is only needed to evade antiviral defences and not directly in replication? After all, both in the PKR and IRF1 knock out clones CypIs still very powerfully suppress HCV replication (albeit in a somewhat higher dose range). One possibility is that here the role of CypA in supporting RNA replication is blocked, thus causing an antiviral effect. In my view it is very difficult to exclude this in the absence of information as to how specifically the CypIs block CypA versus CypB.

b\) (Reviewer \#3) This reviewer is somewhat surprised by the rather marginal effects of CypA KD in Huh7.5 cells on HCV replication. Previous studies e.g. in HCV-adapted Huh7-Lunet (Kaul et al., 2009) or Huh7.5 cells (Gaska et al., 2019 showed) a 100-500 fold decreased in HCV\'s ability to replicate. How do the authors reconcile these data with their own?
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Author response

> Essential revisions:
>
> Below are compiled comments from the three reviewers, each one numbered by general topic. The reviewers have requested that additional experiments be performed to address \#1-3, and possibly \#4, whereas point \#5 can likely be addressed without new experimentation.1) Studies related to further characterizing PKR KO phenotype:
>
> a\) (Reviewer \#1) The Huh7 PKR KO phenotype with respect to viral replication is quite modest. If PKR is a major contributor to the permissivity differences between Huh7 and Huh7.5, then KO of PKR in Huh7.5 cells should have little effect on virus. This would be a good control to include. Along these lines, what is the impact of PKR KO on virus production? A concern is that these modest effects on HCV-luciferase RLU are not likely to have a major effect on virus production. Lastly, can the PKR KO effect be re-constituted with CRISPR-resistant PKR? Does ectopic expression of PKR in Huh7.5 cells make them more Huh7-like?

We thank the reviewer for this comment. Unfortunately, we did not manage to knock out PKR in Huh7.5 cells before the lab was closed due to COVID-19. As the reviewer suggests, we do not expect this to make a difference to HCV replication but we have not managed to test this. We have therefore not been able to further study the role of PKR in distinguishing HCV permissivity of Huh7 and 7.5. We believe that this omission does not impact the conclusions in the manuscript. We have re-iterated that the differences between Huh7 and 7.5 cells are multifactorial with the following text:

"Furthermore, our results suggest that a deficiency in PKR-dependent responses, as well as defective RIG-I (Sumpter et al., 2005), may contribute to Huh7.5 cell permissivity for HCV replication, which is consistent with previous observations showing that RIG-I does not play a role (Binder et al., 2007). Indeed, differences in permissivity between Huh7 and Huh7.5 cells are likely governed by a combination of factors, including RIG-I (Sumpter et al., 2005) and CD81 (Koutsoudakis et al., 2007), among others."

We did over-express PKR in Huh7.5 cells, which inhibited HCV replication. However, we observed that overexpressed PKR was highly active (autophosphorylated) even in the absence of a stimulus, which does not accurately recapitulate the situation in unmodified cells (e.g. Huh7 cells, Figure 7---figure supplement 2A), where PKR is normally inactive (unphosphorylated) until a stimulus is added. Thus, we have not included these particular data in the manuscript as we believe this would complicate the story, without affecting our conclusions about the CypI mechanism. Moreover, these data are similar to those we obtain in the Huh7 PKR KO cells ([Author response image 1](#sa2fig1){ref-type="fig"}), which we have included. We have also discussed the issue of over-expressed PKR being constitutively active as relates to these data.

![Huh7 Cells were transduced with lentiviral vector encoding PKR (pSCRPSY-EIF2AK2); transduced cells were selected by addition of puromycin.\
Expression and activation of PKR was evaluated by Western blot. HCV replication was evaluated as described in the manuscript. HCV replication was slightly decreased in PKR overexpressing Huh7.5 cells. Statistical significance was evaluated by t-test using GraphPad Prism (\*\*\*\* p-value \< 0.0001).](elife-52237-resp-fig1){#sa2fig1}

> b\) (Reviewer \#2) The strongest and most direct piece of evidence supporting the conclusion that HCV uses CypA to evade PKR-dependent antiviral defences rests on Figure 6 and the use of two PKR knock out clones. The presented data show that HCV replication in the two PKR knock out clones is somewhat more resistant to inhibition by CypIs. Concomitantly, the authors show that mRNA induction of IFN-β by HCV is blunted in the PKR KO clones. In the same figure the authors show that a PKR inhibitor decreases the potency of a CypI in parental Huh7 cells but not so much in Huh-7.5 cells (in a previous figure the authors had shown a greater dependence of HCV on CypA in Huh7 compared to Huh-7.5 cells).
>
> Given the high importance of these data for the main conclusion of the manuscript, in my view the authors should consider cell clonal effects, which potentially could confound this important observation. To this end, the authors could restore PKR expression in the knock out clones. One would expect restoration of HCV sensitivity towards CypIs as well as restoration of antiviral signalling. This would lend further support to the role of CypA in modulation PKR functioning and in turn HCV replication.

We thank the reviewer for this important comment. The question of re-expression of PKR in the knockout lines is one we had considered. In the original study, we did not test this because we expected that PKR over-expression would induce translation shutdown as has been described previously (e.g. Grolleau et al., 2000), and would confound our results. Nonetheless, we have now stably over-expressed PKR in Huh7 PKR KO cells and evaluated HCV replication and its sensitivity to CsA inhibition. Over-expressed PKR was highly active, as shown by its robust autophosphorylation even in the absence of a stimulus (Western blot in new Figure 7---figure supplement 2). We found that PKR expression had an inhibitory effect on HCV replication, possibly through suppression of host and viral translation (as evidenced by the autophosphorylation of over-expressed PKR). For this reason, this experiment does not strictly recapitulate the situation in Huh7 cells. That is, the over-expressed PKR is already phosphorylated and activated (see Figure 7---figure supplement 2) instead of un-phosphorylated as in Huh7 cells. Therefore, while PKR over-expression reduced HCV replication, it did not affect HCV sensitivity to CsA. We propose that over-expressed PKR cannot enhance CsA sensitivity, because PKR is already activated and suppressing HCV replication independently of CsA-induced antiviral signaling. We had hoped to examine this further, but did not have time before the COVID-19 closure of the lab.

These data are now shown in Figure 7---figure supplement 2, and we have added the following text:

"We also sought to confirm the role of PKR in CypI activity by over-expressing PKR in Huh7 PKR knockout cells. However, PKR over-expression in itself led to PKR activation, as evidenced by its autophosphorylation (Figure 7---figure supplement 2A). \[...\] This is consistent with previous observations of translation shutdown on PKR overexpression (Grolleau et al., 2000; Barber et al., 1993; Chong et al., 1992; Thomis and Samuel, 1992)."

In the manuscript (originally Figure 6D, now Figure 7D), we observed highly similar results in two PKR KO clones, which were prepared by single-cell cloning. Furthermore, treatment of cells with a PKR inhibitor (originally Figure 6G, now Figure 7G) led to the same phenotype. We also have more new C16 data supporting a role for PKR (Figure 7G). Thus, while the PKR reconstitution experiment did not yield clear results, we propose that together, these data are sufficiently compelling.

> Alternatively/in addition, the authors could over-express PKR in Huh7 cells and explore if this enhances sensitivity to CypIs and also antiviral signalling. Taken together such experiments will extend the foundation of this important conclusion.

As described above, PKR over-expression does not accurately recapitulate the situation in naïve cells in that overexpressed PKR is highly active (autophosphorylated) even in the absence of a stimulus. This makes it difficult to evaluate the effect on the sensitivity of HCV to CypI, which we propose relies on more subtle PKR-mediated activation of IRF1, in the absence of translation shutoff. We have instead focused on an alternative approach to provide further evidence for a role for PKR using the PKR inhibitor C16 (Figure 7G).

> Along similar lines, the experiment displayed in Figure 6G should also include the comparison between Huh7 cells and the Huh7 PKR knock out clones. In support of the model proposed by the authors, one would think that the PKR inhibitor only shifts HCV sensitivity to CypIs in the Huh7 cells expressing functional PKR but not in the knock out clones. Again, this enhances the experimental foundation for the key conclusion of this paper.

This is a very helpful suggestion. We have now compared the effect of the C16 PKR inhibitor in Huh7 and Huh7 knocked out for PKR. The result was as expected and PKR knockout prevents the effect of C16 on CsA sensitivity.

These new data are included as Figure 7G. We have added the following to the text:

"C16 decreased CsA potency in Huh7 cells, but not in Huh7 PKR KO cells (Figure 7G), and only minimally affected CsA potency against HCV in Huh7.5 cells (Figure 7---figure supplement 1)."

> Related to the same Figure 6, the authors should explore if the PKR knock out clones selectively display altered HCV susceptibility to CypIs and not globally to antivirals targeting HCV by different mechanisms (e.g. protease inhibitor, NS5A inhibitor, polymerase inhibitor). While a broad spectrum of different CypIs is already shown in the figure, the authors should consider adding data showing other HCV antivirals.

This is another important point. We have now evaluated the antiviral activities of daclatasvir (NS5A inhibitor) and telaprevir (NS3/4A protease inhibitor) in Huh7 and Huh7 PKR KO cells. As expected, the presence or absence of PKR did not affect HCV sensitivity to these other inhibitors. These data are now shown in Figure 7---figure supplement 3. We have added the following text:

"We next tested whether the absence of PKR broadly affects the sensitivity of HCV to the antiviral activity of telaprevir (NS3/4A protease inhibitor) and daclatasvir (NS5A inhibitor) in Huh7 and Huh7 PKR KO cells. \[...\] Collectively, these data are consistent with a specific role for PKR in the enhanced antiviral activity of CypI in Huh7 cells."

> 2\) Studies related to the conclusion that RLR-MAVS-IFN does not contribute to phenotype:
>
> a\) (Reviewer \#1) Much of Figure 3 is dedicated to showing that induction of IFN-β correlates to CypI potency in Huh7, but not Huh7.5 cells. In Figure 6, the authors state that IFN-β induction in the presence of CypI is mediated by PKR. Then in Figure 7, the authors make the case that the IFN-β induction is actually not important (based on ruxolitinib experiments), but that antiviral gene expression through a PKR-IRF1 axis is the key pathway.
>
> The layout of this story was a bit confusing. If IFN-β ends up having no role in the antiviral activity of CypI, why not put this out there up front in Figure 3? This would make the story more clear. That said, the authors should solidify this claim with IFNAR or STAT1 KO cells as genetic proof that IFN-β has no role. Testing IFN-dependent, but IRF1-independent ISG induction would also be a compelling control. Further, if IFN-β has no role here, then IFN bioassays (i.e., transferring soups and testing for inhibition of IFN-sensitive virus like VSV) would further bolster the claim.

We have now re-structured the manuscript to present the IFN-β/ruxolitinib data earlier, in what is now Figure 4. We have also sought to clarify that the observed phenotype is not dependent on IFN-β signalling and IFN induced gene expression, but is rather a cell-intrinsic response (i.e., gene expression dependent on PKR-IRF1 activation) with IFN-β being one of many antiviral genes induced upon CypI treatment of Huh7, but not Huh7.5 cells. We now show the activation of other antiviral genes, which are predominantly IRF1-dependent, in Figure 4. To confirm that the effect is not mediated by IFN, we performed further experiments using an interferon receptor (IFNAR) blocking antibody. As for ruxolitinib, IFNAR blockade did not affect the CypI potency against HCV, although it did rescue HCV replication from the inhibitory effect of IFN. This data is presented in Figure 4---figure supplement 3.

We have added the following text:

"The notion that IFN was not required for maximal CypI activity was also supported by an experiment using antihuman interferon alpha/beta receptor chain 2 antibody (IFNAR) to inhibit IFN activity through receptor blockade. \[...\] However, in vivo, IFN induction would be expected to influence HCV replication and adaptive immune responses and thus the antiviral activity of CypI in patients."

> b\) (Reviewer \#2) Exclusion that RLR/MAVS-dependent antiviral responses do not play a role is one major conclusion of this study. Therefore, it seems worthwhile to confirm the unresponsiveness of the cells employed here (and published previously) to RLR/MAVS-dependent viral danger signals.
>
> c\) (Reviewer \#3) The authors provide data suggesting that CypI induced antiviral signaling is not dependent on RIGI and MAVS. Important controls would be to show that known RLH agonist actually trigger this pathway in their cells, i.e. the cells are signaling competent.

Unfortunately, we did not manage to complete this experiment before our qPCR machine was requisitioned for COVID-19 testing outside UCL. Nonetheless, RLR/MAVS-dependent antiviral responses have previously been documented in Huh7 cells and we have now cited these studies more prominently. We have added new text reiterating this point:

"Huh7 cells are capable of responding to cytosolic RNA and initiating antiviral signalling through RIG-I, MAVS and IRF3 (Sumpter et al., 2005; Binder et al., 2007). \[...\] Therefore, we first hypothesized that the active RIG-I pathway in Huh7 cells contributes to the antiviral signalling induced by CypI."

> 3\) Studies related to HCV genotype:
>
> (Reviewer \#3) It has been previously been shown that non-JFH1 gts (e.g. Con1) maybe more sensitive to CypA depletion even in Huh7.5 cells. Thus, it would be important to confirm some of the critical data presented here with non-JFH1 based replicons.

We thank the reviewer for this suggestion. We attempted to evaluate replication of the Con1 (genotype 1b) replicon (Lohmann et al. 2003 J. Virol. 77: 3007-3019). Despite significant effort, we were unable to get the Con1 replicon to replicate in our Huh7 and Huh7.5 cells. In the past month, we obtained the Huh7-Lunet cell line, which better supports Con1 replication. We were able to observe weak replication in Huh7-Lunet cells, but ran out of time before the COVID-19 lab closure and were unable to evaluate the effect of CypA depletion or CypI treatment in the presence or absence of PKR in the Huh7-Lunet cell line.

Importantly, Kaul et al., 2009, evaluated replication of the Con1 replicon in CypA-depleted Huh7-Lunet cells and Huh7.5 cells. CypA depletion in Huh7-Lunet cells profoundly inhibited HCV replication by approximately 3 logs at 48 hours, and had a lesser impact in Huh7.5 cells (Kaul et al., 2009, Figure 2B). These data suggest that our findings are relevant for other HCV genotypes and we now cite this study to make this point in the Discussion as follows:

"Notably, a differential requirement for CypA in Huh7-Lunet and Huh7.5 cells has also been observed for replication of genotype 1b (Con1) and genotype 2a (JFH-1) replicons (Kaul et al., 2009), suggesting that these mechanisms are consistent across HCV genotypes."

> 4\) Concern about the claim that this mechanism is broadly applicable to other viruses:
>
> (Reviewer \#3) The authors argue that one of the premises of their study was to investigate the role of CypA for other non-HIV viruses. HCV is arguably a very good example as its dependency on CypA is well established. However, based on the data presented here it is unclear how generalizable CypA-targeted therapies that affect host intrinsic antiviral responses to combat other (RNA) virus infections are. Either additional data are presented to show effects on other viruses or the statements in the manuscript (e.g. Introduction, last paragraph) should be limited to HCV.

We agree with the reviewer that we had over-generalized our conclusions and in fact the mechanisms we have identified here may or may not be applicable to other viruses. To address this concern, we have limited our discussion in the current manuscript to HCV, with the exception of where we have cited literature describing other viruses and CypA.

> 5\) Additional major concerns that may be addressable without new experimentation:
>
> a\) (Reviewer \#2) I was somewhat confused by the authors Discussion related to the differential relevance of CypB and A for HCV infection (subsection "Clarifying the roles of Cyps in HCV replication"). In brief, based on which evidence can the authors conclude that CypA is only needed to evade antiviral defences and not directly in replication? After all, both in the PKR and IRF1 knock out clones CypIs still very powerfully suppress HCV replication (albeit in a somewhat higher dose range). One possibility is that here the role of CypA in supporting RNA replication is blocked, thus causing an antiviral effect. In my view it is very difficult to exclude this in the absence of information as to how specifically the CypIs block CypA versus CypB.

We thank the reviewer for pointing out this lack of clarity in our Discussion. This was partly due to a typographical error where we had mixed up CypA and CypB in the original Discussion. This is now fixed in the new text. To further address this point, we have added a new panel showing that CypA depletion does not impact CsA activity over a CsA dose range in Huh7.5 cells (Figure 1---figure supplement 2), rather than just a single dose as we had shown previously (Figure 1E). We have also clarified the Discussion as follows:

"Here, our data support a direct role for CypB in HCV RNA replication (Watashi et al., 2005), which is consistent with it being equally required in Huh7 and Huh7.5 cells (Figure 1C). In contrast, the requirement for CypA varies according to cell line and appears to be important for evasion of host antiviral responses in innate sensing competent cells (i.e., Huh7) (Figure 1C)."

We have referred to the new data as follows:

"CsA also inhibited HCV replication in Huh7.5 cells silenced for CypA expression (Figure 1E), with similar antiviral potency regardless of CypA expression (Figure 1---figure supplement 2).

> b\) (Reviewer \#3) This reviewer is somewhat surprised by the rather marginal effects of cypA KD in Huh7.5 cells on HCV replication. Previous studies e.g. in HCV-adapted Huh7-Lunet (Kaul et al., 2009) or Huh7.5 cells (Gaska et al., 2019 showed) a 100-500 fold decreased in HCV\'s ability to replicate. How do the authors reconcile these data with their own?

We thank the reviewer for pointing out this oversight in neglecting to include this in our Discussion. Gaska et al., 2019, evaluated the effect of CypA knockdown using HCVcc infection models. CypA has been suggested to be involved in additional steps of HCV infection, such as assembly, which would not have an effect in our replicon assay. In our HCVcc assays, CypA depletion in Huh7.5 cells decreased HCVcc infection by 1-2 logs (Figure 1F), which is consistent with what has been observed in the literature. We have now added a paragraph in the Discussion to reconcile this data with our own:

"CypA has been proposed to have a role in HCV assembly (Nag et al., 2012; Anderson et al., 2011), which is likely reflected by our observation that CypA depletion in Huh7.5 cells decreased HCVcc infection (Figure 1F), but not replication of the HCV replicon (Figure 1C). This is consistent with previous studies showing a large decrease in HCVcc infection in Huh7.5 cells silenced for CypA expression (Gaska et al., 2019)."

With regards to the study by Kaul et al., 2009), only a small decrease in HCV replication in CypA-depleted Huh7.5 cells was observed at 48 hours (Kaul et al., Figure 2A). This is consistent with our data, in that we do see a \~2-fold decrease in HCV replication in Huh7.5 CypA knockdown cells. We have replotted the data on a linear scale and have shown it in [Author response image 2](#sa2fig2){ref-type="fig"} to highlight this point. Kaul et al. observed a more pronounced defect in HCV replication at 48 hours in CypA-depleted Huh7-Lunet cells (Kaul et al. Figure 2A), which is consistent with our observations as well. We have added a sentence to our Discussion to support this:

"Notably, a differential requirement for CypA in Huh7-Lunet and Huh7.5 cells has also been observed for replication of genotype 1b (Con1) replicons and genotype 2a replicons (Kaul et al., 2009), suggesting that these mechanisms are consistent across HCV genotypes."

![HCV replication in CypA-depleted Huh7.5 cells.](elife-52237-resp-fig2){#sa2fig2}

[^1]: Department of Infectious Disease, Section of Virology, Imperial College London, London, United Kingdom.
